Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 24681942)

1.

[Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].

Jomen W, Kuroda H, Matsuno T, Sato M, Yamada M, Abe T, Sakurai T, Fujii S, Maeda M, Fujita M, Kato J, Nojiri S.

Rinsho Ketsueki. 2014 Mar;55(3):360-5. Review.

PMID:
24681942
2.

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N.

Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5.

PMID:
20047097
3.

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.

Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.

PMID:
23810191
4.

Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.

Merx K, Fabarius A, Erben P, Griesshammer M, Reiter A, Hofmann WK, Hehlmann R, Hochhaus A, Lengfelder E.

Ann Hematol. 2013 Jul;92(7):907-15. doi: 10.1007/s00277-013-1725-1. Epub 2013 Mar 24.

PMID:
23525684
5.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.

Blood. 2003 Jun 15;101(12):4701-7. Epub 2003 Feb 6.

6.

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].

Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Chinese.

PMID:
15946498
7.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.

Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Laï JL, Rose C, Preudhomme C.

Leukemia. 2008 Jul;22(7):1454-5. doi: 10.1038/sj.leu.2405088. Epub 2008 Feb 21. No abstract available.

PMID:
18288134
8.

Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.

Caocci G, Atzeni S, Orrù N, Littera R, Culurgioni F, Marongiu F, La Nasa G.

Leuk Res. 2010 Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12. No abstract available.

PMID:
19748671
9.

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R.

Blood. 2005 Mar 1;105(5):2093-8. Epub 2004 Sep 2.

10.

Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.

Soderquist C, Bagg A.

Blood. 2014 Oct 9;124(15):2463. No abstract available.

PMID:
25436260
11.

Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.

Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.

Am J Clin Pathol. 2003 Jun;119(6):833-41.

12.
13.

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K.

Haematologica. 2013 Sep;98(9):1407-13. doi: 10.3324/haematol.2013.085167. Epub 2013 May 28.

14.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
15.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.

16.

Transformation of polycythemia vera to chronic myelogenous leukemia.

Mirza I, Frantz C, Clarke G, Voth AJ, Turner R.

Arch Pathol Lab Med. 2007 Nov;131(11):1719-24.

PMID:
17979493
17.

Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.

Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, Cilloni D, Soverini S, Testoni N, Specchia G, Merante S, Zaccaria A, Frassoni F, Saglio G, Baccarani M.

Ann Oncol. 2006 Mar;17(3):495-502. Epub 2006 Jan 10.

18.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
20.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk